Ángel Fernández-Sanromán

Ángel Fernández-Sanromán

Auto-generated profile, based on publicly available information

Ángel Fernández-Sanromán

Spanish National Cancer Research Centre (CNIO), Madrid, Spain

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
BCBruna Calsina
Bruna Calsina
EPElena Piñeiro-Yáñez
Elena Piñeiro-Yáñez
ÁMÁngel M. Martínez-Montes
Ángel M. Martínez-Montes
ECEduardo Caleiras
Eduardo Caleiras
ÁFÁngel Fernández-Sanromán
Ángel Fernández-Sanromán
MRMercedes Robledo
Mercedes Robledo
The mechanisms triggering metastasis in pheochromocytoma/paraganglioma are unknown, hindering therapeutic options for patients with metastatic tumors (mPPGL). Herein we show by genomic profiling of a large cohort of mPPGLs that high mutational load, microsatellite instability and somatic copy-number alteration burden are associated with ATRX/TERT alterations and are suitable prognostic markers. Transcriptomic analysis defines the signaling networks involved in the acquisition of metastatic competence and establishes a gene signature related to mPPGLs, highlighting CDK1 as an additional mPPGL marker. Immunogenomics accompanied by immunohistochemistry identifies a heterogeneous ecosystem at the tumor microenvironment level, linked to the genomic subtype and tumor behavior. Specifically, we define a general immunosuppressive microenvironment in mPPGLs, the exception being PD-L1 expressing MAML3-related tumors. Our study reveals canonical markers for risk of metastasis, and suggests the usefulness of including immune parameters in clinical management for PPGL prognostication and identification of patients who might benefit from immunotherapy.

9 January 2025 in Cancer Discovery
Verified
Journal Article
Open access
ÁFÁngel Fernández-Sanromán
Ángel Fernández-Sanromán
AFAnnika Fendler
Annika Fendler
BTBenjy J.Y. Tan
Benjy J.Y. Tan
ACAnne-Laure Cattin
Anne-Laure Cattin
CSCharlotte Spencer
Charlotte Spencer
STSamra Turajlic
Samra Turajlic
Although the key aspects of genetic evolution and their clinical implications in clear-cell renal cell carcinoma (ccRCC) are well documented, how genetic features coevolve with the phenotype and tumor microenvironment (TME) remains elusive. Here, through joint genomic–transcriptomic analysis of 243 samples from 79 patients recruited to the TRACERx Renal study, we identify pervasive nongenetic intratumor heterogeneity, with over 40% not attributable to genetic alterations. By integrating tumor transcriptomes and phylogenetic structures, we observe convergent evolution to specific phenotypic traits, including cell proliferation, metabolic reprogramming, and overexpression of putative cGAS–STING repressors amid high aneuploidy. We also uncover a coevolution between the tumor and the T-cell repertoire, as well as a longitudinal shift in the TME from an antitumor to an immunosuppressive state, linked to the acquisition of recurrently late ccRCC drivers 9p loss and SETD2 mutations. Our study reveals clinically relevant and hitherto underappreciated nongenetic evolution patterns in ccRCC. Significance: Using joint genomic–transcriptomic analysis of 243 samples, we reveal recurrent patterns of nongenetic evolution in ccRCC not exclusively governed by genetic factors, including T-cell depletion, tumor T-cell receptor coevolution, potential cGAS–STING repression, and increased cell proliferation. These patterns can aid clinical management and guide novel treatment approaches.

2 October 2025 in Science
Verified
Journal Article
Closed access
EAErnesto López de Alba
Ernesto López de Alba
ISIsrael Salguero
Israel Salguero
DGDaniel Giménez-Llorente
Daniel Giménez-Llorente
JMJavier Montes-Torres
Javier Montes-Torres
ÁFÁngel Fernández-Sanromán
Ángel Fernández-Sanromán
FCFelipe Cortés-Ledesma
Felipe Cortés-Ledesma
The analysis of DNA sequence outcomes provides molecular insights into double-strand break (DSB) repair mechanisms. Using parallel in-pool profiling of Cas9-induced insertions and deletions (indels) within a genome-wide knockout library, we present a comprehensive catalog that assesses the influence of nearly every human gene on DSB repair outcomes. This REPAIRome resource uncovers uncharacterized mechanisms, pathways, and factors involved in DSB repair, including opposing roles for XLF and PAXX, a molecular explanation for Cas9-induced multinucleotide insertions, HLTF functions in Cas9-induced DSB repair, the involvement of the SAGA complex in microhomology-mediated end joining, and an indel mutational signature linked to VHL loss, renal carcinoma, and hypoxia. These results exemplify the potential of REPAIRome to drive future discoveries in DSB repair, CRISPR-Cas gene editing and the etiology of cancer mutational signatures.

9 September 2026 in Nature
Verified
Journal Article
Open access
PDF file
AGAndreas Gruber
Andreas Gruber
AOAndré V Olsen
André V Olsen
BHBarbara Hernando
Barbara Hernando
KCKevin C L Cheng
Kevin C L Cheng
CGClarissa Gerhauser
Clarissa Gerhauser
JWJoachim Weischenfeldt
Joachim Weischenfeldt
Prostate cancer follows a long and heterogeneous disease course with incompletely understood aetiology1. Here we dissect the mutational processes shaping the genomes of 959 donors from the Pan Prostate Cancer Group and assess their clinical relevance. By integrating de novo extracted single-base substitution, insertion–deletion and copy-number signatures with six novel complex structural variant signatures, we identify eight integrated mutational footprints (IMFs) that collectively explain the mutational processes in 85% of primary prostate cancer genomes. IMFs were strongly influenced by regional biases in the genome, most prevalently androgen receptor-mediated mutagenesis and replication stress. Four IMFs, present in 37% of primary tumours, were significantly associated with shorter time to metastasis. These included reactive oxygen-species-driven mutagenesis and both canonical and non-canonical homologous recombination deficiency, the latter being enriched in patients of African ancestry. Extending to the metastatic setting, we found that IMFs predicted sensitivity to androgen receptor pathway inhibitors. Taken together, our study delineates the aetiologies and mutational processes that drive the genomic and clinical heterogeneity of prostate cancer, introduces IMFs as a unifying framework, and highlights their potential to improve both risk stratification and biomarker-guided treatment selection.

27 November 2025 in bioRxiv
Verified
Preprint
Open access
BHBarbara Hernando
Barbara Hernando
BCBlas Chaves-Urbano
Blas Chaves-Urbano
MEMaria Escobar-Rey
Maria Escobar-Rey
MTMarina Torres
Marina Torres
ACAlice Cadiz
Alice Cadiz
GMGeoff Macintyre
Geoff Macintyre
Chromosomal instability (CIN) generates aneuploid genomes that are characteristic of most cancers. While bulk genome sequencing reveals historical CIN, it lacks the resolution to identify ongoing CIN that actively shapes genome evolution. Here, we present a computational framework that leverages single-cell whole-genome sequencing (scWGS) to identify and quantify ongoing CIN by detecting cell-unique copy number alterations and probabilistically mapping them to known CIN signatures. We validated this framework generating in vitro models with four types of induced CIN, correctly identifying the induced-CIN type in each case. When applied to cell lines and organoids with ongoing homologous recombination deficiency, our method showed improved identification of sensitivity to PARP inhibition and platinum-based chemotherapy. Analysing scWGS data from 8 triple-negative breast cancers, we linked ongoing impaired non-homologous end joining to subclonal diversification, a finding further supported in cohorts of 179 unmatched primary and metastatic TNBCs and 39 matched cases. Collectively, our results demonstrate that distinguishing ongoing from historical chromosomal instability uncovers a distinct dimension of tumour evolution, suggesting that effective precision oncology will require integrating measurements of both past genomic scars and active mutational processes.

3 August 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
EAErnesto López de Alba
Ernesto López de Alba
ISIsrael Salguero
Israel Salguero
DGDaniel Giménez-Llorente
Daniel Giménez-Llorente
ÁFÁngel Fernández-Sanromán
Ángel Fernández-Sanromán
ECEster Casajús-Pelegay
Ester Casajús-Pelegay
FCFelipe Cortés-Ledesma
Felipe Cortés-Ledesma
The analysis of DNA sequence outcomes provides molecular insights into double-strand break (DSB) repair mechanisms. By employing parallel in-pool profiling of Cas9-induced indels within a genome-wide knockout library, we present a comprehensive catalog detailing how virtually every human gene influences the DSB repair process. This REPAIRome resource is validated through the identification of novel mechanisms, pathways and factors involved in DSB repair, including unexpected opposing roles for XLF and PAXX in DNA end processing, a molecular explanation for Cas9-induced multi-nucleotide insertions, the identification of HLTF as a DSB-repair factor, the involvement of the SAGA complex in microhomology-mediated end joining, and importantly, an indel mutational signature linked to VHL loss, renal carcinoma and hypoxia. Collectively, these results exemplify the potential of REPAIRome to drive future discoveries in DSB repair, CRISPR-Cas gene editing and the etiology of cancer mutational signatures.